CBAY - CymaBay Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

CymaBay Therapeutics, Inc.

7575 Gateway Boulevard
Suite 110
Newark, CA 94560
United States
510-293-8800
http://www.cymabay.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees43

Key Executives

NameTitlePayExercisedYear Born
Dr. Robert James Wills B.S., M.S., Ph.D.Chairman61kN/A1954
Mr. Sujal A. ShahPres, CEO & Director726.33kN/A1973
Mr. Daniel MenoldVP of Fin.352.39k40k1970
Dr. Charles A. McWherterSr. VP & Chief Scientific Officer580.43kN/A1955
Mr. Paul T. QuinlanGen. Counsel & Corp. Sec.537.91kN/A1963
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar, a selective agonist of peroxisome proliferator-activated receptor delta, which has completed Phase II clinical study for the treatment of primary biliary cholangitis, as well as patients with nonalcoholic steatohepatitis. The company also develops MBX-2982, a selective orally-active G protein-coupled receptor agonist that interacts with bioactive lipids known to stimulate glucose-dependent insulin secretion for the treatment of gut/liver disease. Its preclinical stage product candidate is CB-001, a G protein-coupled receptor for omega-3 fatty acids, such as docosahexaenoic acid for the treatment of gut/liver disease. It has development and licensing agreement with Janssen Pharmaceuticals, Inc. to develop and discover undisclosed metabolic disease target agonists for the treatment of type II diabetes and other disorders; and a license agreement with DiaTex, Inc. to develop and commercialize therapeutic products comrprising halofenate and its enantiomers, derivatives, and analogs for the treatment of diseases. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.

Corporate Governance

CymaBay Therapeutics, Inc.’s ISS Governance QualityScore as of June 25, 2019 is 7. The pillar scores are Audit: 2; Board: 4; Shareholder Rights: 6; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.